Pages that link to "Q34000417"
Jump to navigation
Jump to search
The following pages link to Immunotoxin treatment of cancer (Q34000417):
Displaying 50 items.
- Thrombotic microangiopathy with targeted cancer agents (Q24635904) (← links)
- Cancer-associated thrombotic microangiopathy (Q26738984) (← links)
- Ribosome-inactivating proteins: from plant defense to tumor attack (Q26828935) (← links)
- Toxin-based targeted therapy for malignant brain tumors (Q27006226) (← links)
- Toxin-based therapeutic approaches (Q27013664) (← links)
- The 1.8 A Cholix Toxin Crystal Structure in Complex with NAD+ and Evidence for a New Kinetic Model (Q27678743) (← links)
- Cholera- and anthrax-like toxins are among several new ADP-ribosyltransferases (Q28476469) (← links)
- Chemical Screens Identify Drugs that Enhance or Mitigate Cellular Responses to Antibody-Toxin Fusion Proteins (Q28553712) (← links)
- Rise and fall of an anti-MUC1 specific antibody (Q28743508) (← links)
- Modern Technologies for Creating Synthetic Antibodies for Clinical application (Q30467308) (← links)
- Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy (Q33311571) (← links)
- Crystallization and preliminary X-ray diffraction data analysis of stenodactylin, a highly toxic type 2 ribosome-inactivating protein from Adenia stenodactyla (Q33522545) (← links)
- A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer (Q33689021) (← links)
- Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial (Q33732575) (← links)
- Fusogenics: a recombinant immunotoxin-based screening platform to select internalizing tumor-specific antibody fragments (Q33763294) (← links)
- Interstitial infusion of glioma-targeted recombinant immunotoxin 8H9scFv-PE38. (Q33828459) (← links)
- Challenging the roles of CD44 and lipolysis stimulated lipoprotein receptor in conveying Clostridium perfringens iota toxin cytotoxicity in breast cancer (Q33864348) (← links)
- Anti-tumor activity of an immunotoxin (TGFα-PE38) delivered by attenuated Salmonella typhimurium (Q33914020) (← links)
- Pseudomonas exotoxin A-mediated apoptosis is Bak dependent and preceded by the degradation of Mcl-1 (Q33963772) (← links)
- Delivery of ricin toxin a-chain by peptide-targeted mesoporous silica nanoparticle-supported lipid bilayers (Q33993918) (← links)
- Production of unique immunotoxin cancer therapeutics in algal chloroplasts (Q34034756) (← links)
- Photochemical internalization of tumor-targeted protein toxins. (Q34068201) (← links)
- Short communication: Activating stimuli enhance immunotoxin-mediated killing of HIV-infected macrophages (Q34085094) (← links)
- ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol. (Q34144923) (← links)
- Recombinant adenovirus IL-24-Bax promotes apoptosis of hepatocellular carcinoma cells in vitro and in vivo (Q34238776) (← links)
- An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies (Q34276680) (← links)
- Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties (Q34575951) (← links)
- Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P. (Q35018336) (← links)
- Development of a novel DDS for site-specific PEGylated proteins (Q35040200) (← links)
- Targeted inhibition of CD133+ cells in oral cancer cell lines (Q35129213) (← links)
- An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer (Q35130286) (← links)
- Site-specific modification of ED-B-targeting antibody using intein-fusion technology (Q35158352) (← links)
- Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis (Q35170403) (← links)
- Design and evaluation of a peptide-based immunotoxin for breast cancer therapeutics (Q35244073) (← links)
- Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates (Q35446333) (← links)
- Immunotoxins and anticancer drug conjugate assemblies: the role of the linkage between components (Q35459059) (← links)
- Passive and active vaccination strategies to prevent ricin poisoning (Q35459324) (← links)
- Cargo-delivery platforms for targeted delivery of inhibitor cargos against botulism (Q35542237) (← links)
- The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan (Q35578041) (← links)
- Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy. (Q35653164) (← links)
- A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas (Q35746801) (← links)
- A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity. (Q35747230) (← links)
- Mesothelin-targeted agents in clinical trials and in preclinical development (Q35815380) (← links)
- Immunotoxins constructed with chimeric, short-lived anti-CD22 monoclonal antibodies induce less vascular leak without loss of cytotoxicity (Q35918856) (← links)
- Gigantoxin-4-4D5 scFv is a novel recombinant immunotoxin with specific toxicity against HER2/neu-positive ovarian carcinoma cells (Q35985081) (← links)
- Selective killing of Kaposi's sarcoma-associated herpesvirus lytically infected cells with a recombinant immunotoxin targeting the viral gpK8.1A envelope glycoprotein (Q35992503) (← links)
- Targeted cytotoxic therapy: adapting a rapidly progressing anticancer paradigm for depletion of persistent HIV-infected cell reservoirs (Q36073562) (← links)
- Affitoxin--a novel recombinant, HER2-specific, anticancer agent for targeted therapy of HER2-positive tumors (Q36108466) (← links)
- Hematopoietic cell kinase (HCK) as a therapeutic target in immune and cancer cells. (Q36140620) (← links)
- Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma (Q36157337) (← links)